| 000 | 05413cam a2200781 i 4500 | ||
|---|---|---|---|
| 005 | 20250919132325.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 190918s2016 enk ob 001 0 eng | ||
| 010 | _a2015-041033 | ||
| 020 | _a9781118924952 (ePub) | ||
| 020 | _a1118924959 (ePub) | ||
| 020 | _a9781118924976 (Adobe PDF) | ||
| 020 | _a1118924975 (Adobe PDF) | ||
| 020 | _z9781118912034 (pbk.) | ||
| 020 | _a9781118924938 | ||
| 020 | _a1118924932 | ||
| 020 | _a1118912039 (pbk.) | ||
| 020 | _a9781118912034 (pbk.) | ||
| 029 | 1 |
_aDEBBG _bBV043628907 |
|
| 029 | 1 |
_aDEBBG _bBV043738112 |
|
| 035 |
_a(OCoLC)925785722 _z(OCoLC)943826450 |
||
| 035 | _a(OCoLC)ocn925785722 | ||
| 039 | 9 |
_a201911051450 _bmurni _c201911051427 _dmurni _y09-18-2019 _zhafiz _wUKM UBCM Wiley MARC (363 titles).mrc _x79 |
|
| 040 |
_aDLC _beng _erda _cDLC _dNST _dYDXCP _dEBLCP _dDG1 _dOCLCO _dRECBK _dCOO _dOCLCF _dDEBBG _dKSU |
||
| 042 | _apcc | ||
| 049 | _aMAIN | ||
| 050 | 0 | 0 | _aRC848.F3 |
| 060 | 1 | 0 | _aWI 700 |
| 072 | 7 |
_aHEA _x039000 _2bisacsh |
|
| 072 | 7 |
_aMED _x014000 _2bisacsh |
|
| 072 | 7 |
_aMED _x022000 _2bisacsh |
|
| 072 | 7 |
_aMED _x112000 _2bisacsh |
|
| 072 | 7 |
_aMED _x045000 _2bisacsh |
|
| 082 | 0 | 0 |
_a616.3/62 _223 |
| 245 | 0 | 0 |
_aClinical dilemmas in non-alcoholic fatty liver disease / _c[edited by] Roger Williams, Simon Taylor-Robinson. |
| 264 | 1 |
_aChichester, West Sussex, UK ; _aHoboken, NJ : _bJohn Wiley & Sons Inc., _c2016. |
|
| 300 | _a1 online resource. | ||
| 336 |
_atext _2rdacontent |
||
| 337 |
_acomputer _2rdamedia |
||
| 338 |
_aonline resource _2rdacarrier |
||
| 490 | 1 | _aClinical Dilemmas (UK) | |
| 504 | _aIncludes bibliographical references and index. | ||
| 505 | 0 | _aHype or harm from fatty liver disease? / Stephen H Caldwell and Curt Argo -- Worldwide problem / Geoffrey Farrell and Philip Newsome -- Is insulin resistance the key motive for NAFLD? / Desmond Johnston -- Progression to cirrhosis is more likely in children with NAFLD? / Anil Dhawan -- NAFLD as cause of cryptogenic cirrhosis? / Jay Lefkowitch -- Is NAFLD different in absence of metabolic syndrome? / Yusuf Yilmaz -- Occurrence of noncirrhotic HCC in NAFLD / Stephen Harrison and Dawn Torres -- Fibrosis progression molecular pathways all important? / Anna-Mae Diehl and Dr Wing-Kin Syn -- Can fatty liver of NAFLD be distinguished from that of alcoholic liver disease? / David Kleiner and Elizabeth Brunt -- Are inflammasomes and intestinal microbiota relevant in disease progression to NASH? / M. Bilal Siddiqui, M. Shadab Siddiqui and Arun Sanyal -- Can genetic influence in non-alcoholic fatty liver disease be ignored? / Quentin Anstee -- Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? / Soo Lim -- Is there a best method for diagnosis of NAFLD? / Vlad Ratziu -- Choice of non-invasive blood tests and FibroScan / Massimo Pinzani and Manolis Tsocatzis -- Are the guidelines AASLD, IASL, EASL and BSG of help? / Jean-Francois Dufour -- How to choose from different imaging modalities and screening techniques / Hero Hussain -- Are the pros outweighed by the cons of obtaining a liver biopsy? / Simon Taylor-Robinson and Jeremy Cobbold -- Screening for NAFLD in high risk population / Nader Lessan -- Balancing calorie restriction, exercise and weight reduction / Nicholas Finer -- Should physicians be prescribing, or patients self-medicating with Orlistat, vitamin E, vitamin D, insulin antagonist, Trental and coffee? / Brent Neuschwander-Tetri and Haripriya Maddur -- Does improvement in hepatic steatosis have a significant favourable effect on the metabolic syndrome, including diabetes? / Jukka Westerbacka -- What are the dangers as well as the true benefits of bariatric surgery? / Andrew Jenkinson -- Liver transplantation : what can it offer? / Roger Williams -- Molecular antagonists, leptin or other hormones in supplementing environmental factors? / Jeremy Tomlinson -- Use of antifibrotic agents in clinical practice / Jonathan Fallowfield -- Better understanding of early development and material influence? / Jude Oben -- Defining the role of metabolic physician / Nicholas Finer. | |
| 588 | _aDescription based on print version record and CIP data provided by publisher. | ||
| 650 | 0 | _aFatty Liver. | |
| 650 | 7 |
_aHEALTH & FITNESS _xDiseases _xGeneral. _2bisacsh |
|
| 650 | 7 |
_aMEDICAL _xClinical Medicine. _2bisacsh |
|
| 650 | 7 |
_aMEDICAL _xDiseases. _2bisacsh |
|
| 650 | 7 |
_aMEDICAL _xEvidence-Based Medicine. _2bisacsh |
|
| 650 | 7 |
_aMEDICAL _xInternal Medicine. _2bisacsh |
|
| 650 | 7 |
_aFatty liver. _2fast _0(OCoLC)fst00921974 |
|
| 650 | 2 | _aNon-alcoholic Fatty Liver Disease. | |
| 655 | 4 | _aElectronic books. | |
| 655 | 0 | _aElectronic books. | |
| 700 | 1 |
_aWilliams, Roger, _d1931- _eeditor. |
|
| 700 | 1 |
_aTaylor-Robinson, Simon D., _eauthor. |
|
| 773 | 0 | _tWiley e-books | |
| 776 | 0 | 8 |
_iPrint version: _tClinical dilemmas in non-alcoholic fatty liver disease _dChichester, West Sussex ; Hoboken, NJ : John Wiley & Sons Inc., 2016 _z9781118912034 _w(DLC) 2015040510 |
| 830 | 0 | _aClinical Dilemmas (UK) | |
| 856 | 4 | 0 |
_uhttps://eresourcesptsl.ukm.remotexs.co/user/login?url=https://doi.org/10.1002/9781118924938 _zWiley Online Library |
| 907 |
_a.b16755728 _b2022-10-11 _c2019-11-12 |
||
| 942 | _n0 | ||
| 914 | _avtls003651229 | ||
| 998 |
_ae _b2019-05-09 _cm _dz _feng _genk _y0 _z.b16755728 |
||
| 999 |
_c643459 _d643459 |
||